CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer

PURPOSE: Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only two years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Michaels, Alex D., Newhook, Timothy E., Adair, Sara J., Morioka, Sho, Goudreau, Bernadette J., Nagdas, Sarbajeet, Mullen, Matthew G., Persily, Jesse B., Bullock, Timothy N. J., Slingluff, Craig L., Ravichandran, Kodi S., Thomas Parsons, J., Bauer, Todd W.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296745/
https://ncbi.nlm.nih.gov/pubmed/29288236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2283
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars